Evidence map›Paper›PMID 39175908›Full record

ArticleFrontiers in public health2024

Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19.

Shehzad M Iqbal, Andrew M Rosen, Darin Edwards, Ana Bolio, Heidi J Larson, Mariana Servin, Marcy Rudowitz, Andrea Carfi, Francesca Ceddia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shehzad M IqbalModerna, Inc., Cambridge, MA, United States.
Andrew M RosenModerna, Inc., Cambridge, MA, United States.
Darin EdwardsModerna, Inc., Cambridge, MA, United States.
Ana BolioLondon School of Hygiene and Tropical Medicine, University of London, London, United Kingdom.
Heidi J LarsonLondon School of Hygiene and Tropical Medicine, University of London, London, United Kingdom.
Mariana ServinModerna, Inc., Cambridge, MA, United States.
Marcy RudowitzModerna, Inc., Cambridge, MA, United States.
Andrea CarfiModerna, Inc., Cambridge, MA, United States.
Francesca CeddiaModerna, Inc., Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The messenger RNA (mRNA) platform emerged at the forefront of vaccine development during the COVID-19 pandemic, with two mRNA COVID-19 vaccines being among the first authorized globally. These vaccines were developed rapidly. Informed by decades of laboratory research, and proved to be safe and efficacious tools for mitigating the global impact of the COVID-19 pandemic. The mRNA platform holds promise for a broader medical application beyond COVID-19. Herein, we provide an overview of this platform and describe lessons learned from the COVID-19 pandemic to help formulate strategies toward enhancing uptake of future mRNA-based interventions. We identify several strategies as vital for acceptance of an expanding array of mRNA-based vaccines and therapeutics, including education, accurate and transparent information sharing, targeted engagement campaigns, continued investment in vaccine safety surveillance, inclusion of diverse participant pools in clinical trials, and addressing deep-rooted inequalities in access to healthcare. We present findings from the Global Listening Project (GLP) initiative, which draws on quantitative and qualitative approaches to capture perceptions and experiences during the COVID-19 pandemic to help design concrete action plans for improving societal preparedness for future emergencies. The GLP survey (>70,000 respondents in 70 countries) revealed tremendous disparities across countries and sociodemographic groups regarding willingness to accept novel mRNA vaccines and medicines. The comfort in innovations in mRNA medicines was generally low (35%) and was marginally lower among women (33%). The GLP survey and lessons learnt from the COVID-19 pandemic provide actionable insights into designing effective strategies to enhance uptake of future mRNA-based medicines.

Indexed as

COVID-19COVID-19 VaccinesmRNA VaccinesSARS-CoV-2HumansRNA, MessengerVaccines, SyntheticCOVID-19 VaccinesmRNA VaccinesRNA, MessengerVaccines, SyntheticCOVID-19mRNA vaccine developmentmRNA vaccines and therapeuticspublic trustvaccine confidencevaccine hesitancy

Identifiers

PMID39175908
PMCPMC11340501

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.